about
Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in RwandaThe role of social capital in successful adherence to antiretroviral therapy in Africa.Convergence of mortality rates among patients on antiretroviral therapy in South Africa and North AmericaPrevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral regimens and feeding options in RwandaHuman breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized miceAttrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infectionEfficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsAntiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT miceProvision of antiretroviral treatment in conflict settings: the experience of Médecins Sans FrontièresSupporting the massive scale-up of antiretroviral therapy: the evolution of PEPFAR-supported treatment facilities in South Africa, 2005-2009Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited settingIncidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North AmericaA randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in UgandaEfficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisAIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral TherapyContribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral TreatmentAdherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic reviewHigh multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacyAntiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewSoaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countriesAntiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research prioritiesThe impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapyProlongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing actEconomic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature reviewAntiretroviral Agents — How Best to Protect Infants from HIV and Save Their Mothers from AIDSCell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapyAntiretroviral adherence in a resource-poor settingAntiretroviral interventions for preventing breast milk transmission of HIVOptimisation of antiretroviral therapy in HIV-infected children under 3 years of ageTask shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapyOptimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years oldAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesOptimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitisMobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infectionAntiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individualsEffectiveness of antiretroviral therapy in HIV-infected children under 2 years of ageInterventions to improve adherence to antiretroviral therapy in children with HIV infectionAntiretroviral therapy for prevention of HIV transmission in HIV-discordant couplesTenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals
P921
P924
Q21034168-527D676B-5343-41B6-B159-A6D6594D2746Q21034179-A784446E-B81E-44C0-928D-19EB66EAC55EQ21034185-70E68653-1CBC-48B3-BF4F-25E5FBFA61B5Q21034187-22AA244B-972E-44B7-B2CB-23DF06365C22Q21131400-7AB56BA1-DB43-45C9-9CA3-C99367898F6BQ21134515-28789D7E-207D-45A5-95BC-D3C281C56E6DQ21142645-82750EE4-79F4-44EB-8C27-2BD601CBFD2BQ21144607-9B835C15-BAF0-4B0F-A2A0-0762BAD1EEABQ21144657-FF1E26C7-FFB6-481A-9C57-62798AC444A1Q21202765-DBDD411B-C36F-4383-96C4-7B97FB460EE5Q21257287-2B5EF83B-D64B-426D-B688-CBC0D17A9455Q21284831-BD7D20F8-AA7F-448A-B2DD-3A27AC531BA1Q21521430-13405D23-E0ED-4D81-AFBD-12F8A64B230AQ21559730-F62F4681-CB6A-4798-B63B-EA3018B4E857Q21999480-2D4C6CB6-3078-4714-A087-7685F14607B5Q22241462-224A79E6-E8B1-4095-A5B8-771B9AB17DD2Q22242229-F4743BAA-1103-44AE-B8B2-970041837DB0Q22242638-5D74616E-F461-4906-9E83-62D189EF523EQ22242698-7053DE65-4038-40F6-B464-B1E933EB0DF5Q22242702-8882049A-887A-4392-993D-02BCC0B15987Q22242737-B0CE791F-52F8-4AA7-9C58-0D0C71AB6BF3Q22242738-5AC01AE6-2F53-470A-B136-3E6BF93A80F2Q22242809-F47786DA-4B17-41EA-B7D0-EA81B0E5BED9Q22242863-DD875C8F-AEB7-427E-B2D8-91999D5B762CQ22248034-B2F1151E-35DE-4A79-A874-BEDD8C053A67Q22250894-A82D3E7A-1077-4276-8A08-1D8A8DB2A4F8Q22251085-1C136A2E-536C-4F4C-B6C3-461A43A30C3AQ22252605-96AC187F-8306-4A11-9D8F-07EA42642DD7Q22252958-B7A0D09B-461E-49CB-9075-EFA67C7776A0Q24194589-38AD079E-9031-4B49-AB01-077B879D491CQ24194925-57AE78D9-6D4D-499C-BFA7-73576718D916Q24197527-55CFB2F4-F0A6-400B-8534-42543BF50F85Q24197939-8339694C-761F-42D9-A915-ECCF4572941CQ24200929-1617AB7D-F925-408E-87B9-49A08C8650FBQ24201026-6154F9F3-FD0A-490E-9C4D-CCC9744631FFQ24201955-CCC9865E-73D5-47B5-8A75-B51C78D3345EQ24202004-BAFD4DD8-8AB3-41B4-A01B-8A5DAA340320Q24234320-075D2146-5F06-4806-8D63-00F59DE18261Q24234597-B524E6D4-EEFE-4674-9313-C225F771742BQ24234651-08B0EE1A-A4CD-42BA-AC35-07D26BD50B09
P921
description
Agent actif contre les rétrovirus
@fr
pharmaceutical compound active against retroviruses
@en
name
Antirétroviral
@fr
antiretroviral drug
@en
antiretroviral
@ca
antiretroviralt legemiddel
@nn
antiretroviralt läkemedel
@sv
kontraŭretrovirusa medikamento
@eo
type
label
Antirétroviral
@fr
antiretroviral drug
@en
antiretroviral
@ca
antiretroviralt legemiddel
@nn
antiretroviralt läkemedel
@sv
kontraŭretrovirusa medikamento
@eo
prefLabel
Antirétroviral
@fr
antiretroviral drug
@en
antiretroviral
@ca
antiretroviralt legemiddel
@nn
antiretroviralt läkemedel
@sv
kontraŭretrovirusa medikamento
@eo